Skip to main content
SpringerLink
Log in

Morphea and Scleroderma

  • Chapter
  • First Online:
Evidence-Based Procedural Dermatology

  • 1365 Accesses

Abstract

Morphea and scleroderma are a spectrum of autoimmune connective tissue disorders hallmarked by tissue fibrosis. Morphea is localized to the skin, subcutaneous tissues, and occasionally, deeper, directly underlying structures such as muscle and bone. In contrast, scleroderma is characterized by systemic involvement, including the vasculature and internal organs (1a) (Fett, Clin Dermatol 31:432–437, 2013). Treatment largely depends upon the extent of disease, with minor cases of morphea requiring observation and systemic sclerosis requiring potent immunosuppressive medications. Although an exhaustive discussion of medical therapies for this spectrum of diseases is beyond the scope of this chapter, surgeries and laser therapy are important components of comprehensive care of these patients. The cosmetic and functional sequelae of morphea and scleroderma can be extensive, and the procedural dermatologist is in a unique position to reverse some of the manifestations of these debilitating diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):432–7.

    PubMed  Google Scholar 

  2. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70(11):1068–76.

    CAS  PubMed  Google Scholar 

  3. Fett N, Werth WP. Update on morphea: part 1. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217–28.

    PubMed  Google Scholar 

  4. Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24:73–80.

    CAS  PubMed  Google Scholar 

  5. Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006;45:612–20.

    Google Scholar 

  6. Leitenberger JJ, Cayce RL, Haley RW, Adams-Hueet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145:545–50.

    PubMed  PubMed Central  Google Scholar 

  7. Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13:171–6.

    PubMed  Google Scholar 

  8. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246–55.

    PubMed  Google Scholar 

  9. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9(5):A311–8.

    PubMed  Google Scholar 

  10. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223–35.

    PubMed  Google Scholar 

  11. Mayes MD. Classification and epidemiology of scleroderma. Semin Cutan Med Surg. 1998;17(1):22–6.

    CAS  PubMed  Google Scholar 

  12. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–55.

    PubMed  Google Scholar 

  13. Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. Curr Opin Rheumatol. 2014;26(6):646–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71:1355–60.

    PubMed  Google Scholar 

  15. Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther. 2011;13:R172.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Varga J. Scleroderma: from pathogenesis to comprehensive management. New York: Springer; 2012.

    Google Scholar 

  17. Winter R. Scleroderma: symptoms, diagnosis and treatment. Hauppauge: Nova Science Publishers; 2013.

    Google Scholar 

  18. McCray CJ, Mayes MD. Update on systemic sclerosis. Curr Allergy Asthma Rep. 2015;15(5):25.

    PubMed  Google Scholar 

  19. Wigley FM, Flavahan NA. Raynaud’s phenomenon. N Engl J Med. 2016;375:556–65.

    CAS  PubMed  Google Scholar 

  20. Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015;90(1):62–73.

    PubMed  PubMed Central  Google Scholar 

  21. Sivek R, Emer J. Use of a blunt-tipped microcannula for soft tissue filler injection in the treatment of linear scleroderma (en coup de sabre). Dermatol Surg. 2014;40(12):1439–41.

    CAS  PubMed  Google Scholar 

  22. Thareja SK, Sadhwani D, Alan Fenske N. En coup de sabre morphea treated with hyaluronic acid filler. Report of a case and review of the literature. Int J Dermatol. 2015;54(7):823–6.

    PubMed  Google Scholar 

  23. Franco JP, Serra MS, Lima RB, D’Acri AM, Martins CJ. Scleroderma en coup de sabre treated with polymethylacrylate – case report. Ann Bras Dermatol. 2016;91(2):209–11.

    Google Scholar 

  24. Al-Niaimi F, Taylor JA, Lyon CC. Idiopathic hemifacial atrophy treated with permanent polyacrylamide subdermal filler. Dermatol Surg. 2012;38(11):143–5.

    CAS  PubMed  Google Scholar 

  25. Ibler KS, Gramkow C, Siemssen PA. Autologous fat transplantation for the treatment of linear scleroderma en coup de sabre. Skinmed. 2015;13(1):74–6.

    PubMed  Google Scholar 

  26. Consorti G, Tieghi R, Clauser L. Frontal linear scleroderma: long-term result in volumetric restoration of the fronto-orbital area by structural fat grafting. J Craniofac Surg. 2012;23:e263–5.

    PubMed  Google Scholar 

  27. Lapiere JC, Aasi S, Cook B, Montalvo A. Successful correction of depressed scars of the forehead secondary to trauma and morphea en coup de sabre by en bloc autologous dermal fat graft. Dermatol Surg. 2000;26(8):793–7.

    CAS  PubMed  Google Scholar 

  28. Mertens JS, Seyger MM, Kievit W, Hoppenreijs EP, Jansen TL, van de Kerkhof PC, Radstake TR, de Jong EM. Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. Br J Dermatol. 2015;172(3):722–8.

    CAS  PubMed  Google Scholar 

  29. Choksi AN, Orringer JS. Linear morphea-induced atrophy treated with hyaluronic acid filler injections. Dermatol Surg. 2011;37(6):880–3.

    CAS  PubMed  Google Scholar 

  30. Barin EZ, Cinal H, Cakmak MA, Tan O. Treatment of linear scleroderma (en coup de sabre) with dermal fat grafting. J Cutan Med Surg. 2016;20(3):269–71.

    PubMed  Google Scholar 

  31. Roh MR, Jung JY, Chung KY. Autologous fat transplantation for depressed linear scleroderma-induced facial scars. Dermatol Surg. 2008;34(12):1659–65.

    CAS  PubMed  Google Scholar 

  32. Shiffman MA. Autologous fat transfer: art, science, and clinical practice. Berlin/Heidelberg: Springer; 2010.

    Google Scholar 

  33. Cavusoglu T, Yazici I, Vargel I, Karakaya EI. Reconstruction of coup de sabre deformity (linear localized scleroderma) by using galeal frontalis muscle flap and demineralized bone matrix combination. J Plast Reconstr Aesthet Surg. 2009;62(2):e25–8.

    Google Scholar 

  34. Baek R, Heo C, Kim BK. Use of various free flaps in progressive hemifacial atrophy. J Craniofac Surg. 2011;22(6):2268–71.

    PubMed  Google Scholar 

  35. Danino AM, Ichinose M, Yoshimoto S, Wako M, Servant JM. Repair of wide coup de sabre without cutaneous excision by means of pericranial-galeal padding flap. Plast Reconstr Surg. 1999;104(7):2108–11.

    CAS  PubMed  Google Scholar 

  36. Agostini T, Spinelli G, Marino G, Perello R. Esthetic restoration in progressive hemifacial atrophy (Romberg disease): structural fat grafting versus local/free flaps. J Craniofac Surg. 2014;25(3):783–7.

    PubMed  Google Scholar 

  37. Sengezer M, Deveci M, Selmanpakoglu N. Repair of “coup de sabre,” a linear form of scleroderma. Ann Plast Surg. 1996;37(4):428–32.

    CAS  PubMed  Google Scholar 

  38. Hwang DY, Paik HW, Byeon JH. Correction of facial linear scleroderma ‘coup de sabre’ with BoneSource. J Craniofac Surg. 2012;23(3):e263–5.

    Google Scholar 

  39. Slack GC, Tabit CJ, Allam KA, Kawamoto HK, Bradley JP. Parry-Romberg reconstruction: optimal timing for hard and soft tissue procedures. J Craniofac Surg. 2012;23(7):1969–73.

    PubMed  Google Scholar 

  40. Chung L, Fiorentio D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev. 2006;5(2):125–8.

    PubMed  Google Scholar 

  41. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum. 2002;46(9):2410–20.

    PubMed  Google Scholar 

  42. Ferri C, Valentini G, Cozi F, Sebastiani M, Michelassi C, La MG, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine. 2002;81(2):139–53.

    PubMed  Google Scholar 

  43. Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol. 2015;11:146–58.

    PubMed  Google Scholar 

  44. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841–7.

    CAS  PubMed  Google Scholar 

  45. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72:1696–9.

    CAS  PubMed  Google Scholar 

  46. Engelhart M. The effect of sympathetic blockade and cooling in Raynaud’s phenomenon. Clin Physiol. 1990;10(2):131–6.

    CAS  PubMed  Google Scholar 

  47. Klyscz T, Junger M, Meyer H, Rassner G. Improvement of acral circulation in a patient with systemic sclerosis with stellate blocks. Vasa. 1998;27(1):39–42.

    CAS  PubMed  Google Scholar 

  48. Omote K, Kawamata M, Namiki A. Adverse effects of stellate ganglion block on Raynaud’s phenomenon associated with progressive systemic sclerosis. Anesth Analg. 1993;77(5):1057–60. En

    CAS  PubMed  Google Scholar 

  49. Coveliers HM, Hoexum F, Nederhoed JH, Wisselink W, Rauwerda JA. Thoracic sympathectomy for digital ischemia: a summary of evidence. J Vasc Surg. 2011;54(1):273–7.

    PubMed  Google Scholar 

  50. Wasserman A, Brahn E. Systemic sclerosis: bilateral improvement of Raynaud’s phenomenon with unilateral digital sympathectomy. Semin Arthritis Rheum. 2010;40(2):137–46.

    PubMed  Google Scholar 

  51. Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol. 2003;30(8):1788–92.

    PubMed  Google Scholar 

  52. Merritt WH. Role and rationale for extended periarterial sympathectomy in the management of severe Raynaud syndrome: techniques and results. Hand Clin. 2015;31(1):101–20.

    PubMed  Google Scholar 

  53. Stone AV, Koman LA, Callahan MF, Eckman DM, Smith BP, Plate JF, Smith TL. The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012;37(4):795–802.

    PubMed  Google Scholar 

  54. Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma. J Hand Surg Eur. 2014;39:876–80.

    CAS  Google Scholar 

  55. Zebryk P, Puszczewicz MJ. Botulinum toxin A in the treatment of Raynaud’s phenomenon: a systematic review. Arch Med Sci. 2016;12(4):864–70.

    PubMed  Google Scholar 

  56. Van Beek AL, Lim PK, Gear AJ, et al. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007;119:217–26.

    PubMed  Google Scholar 

  57. Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg Am. 2009;34:446–52.

    PubMed  Google Scholar 

  58. Neumeister MW. Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg Am. 2010;35:2085–92.

    PubMed  Google Scholar 

  59. Serri J, Legre R, Veit V, et al. Botulinum toxin type A contribution in the treatment of Raynaud’s phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013;58:658–62.

    CAS  PubMed  Google Scholar 

  60. Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum. 2012;41(6):822–9.

    PubMed  Google Scholar 

  61. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol. 2011;65(1):15–22.

    PubMed  Google Scholar 

  62. Saddic N, Miller JJ, Miller OF 3rd, Clarke JT. Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome. Arch Dermatol. 2009;145(2):212–3.

    PubMed  Google Scholar 

  63. Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol. 2005;32(4):642–8.

    PubMed  Google Scholar 

  64. Chamberlain AJ, Walker NP. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg. 2003;29(9):968–70.

    PubMed  Google Scholar 

  65. Bottomley WW, Goodfield MJ, Sheehan-Dare RA. Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol. 1996;135(2):302–4.

    CAS  PubMed  Google Scholar 

  66. Sparsa A, Lesaux N, Kessler E, Bonnetblanc JM, Blaise S, Lebrun-Ly V, et al. Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol. 2005;53(5):S263–5.

    PubMed  Google Scholar 

  67. Sultan-Bichat N, Menard J, Perceau G, Staerman F, Bernard P, Reguiai Z. Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol. 2012;66(3):424–9.

    PubMed  Google Scholar 

  68. Ciatti S, Varga J, Greenbaum SS. The 585 nm flashlamp-pumped pulsed dye laser for the treatment of telangiectasias in patients with scleroderma. J Am Acad Dermatol. 1996;35(3):487–8.

    CAS  PubMed  Google Scholar 

  69. Halachmi S, Gabari O, Cohen S, Koren R, Amitai DB, Lapidoth M. Telangiectasias in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. Lasers Med Sci. 2014;29(1):137–40.

    PubMed  Google Scholar 

  70. Murray AK, Moore TL, Richards H, Ennis H, Griffiths CE, Herrick AL. Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectasias. Br J Dermatol. 2012;167(3):563–9.

    CAS  PubMed  Google Scholar 

  71. Dinsdale G, Murray A, Moore T, Ferguson J, Wilkinson J, Richards H, et al. A comparison of intense pulsed light and laser treatment of telangiectasias in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology (Oxford). 2014;53(8):1422–30.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Rachel Kyllo

  2. Division of Dermatology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA

    Martha Laurin Council

Authors
  1. Rachel Kyllo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martha Laurin Council
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martha Laurin Council .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Northwestern University, Chicago, IL, USA

    Murad Alam

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kyllo, R., Council, M.L. (2019). Morphea and Scleroderma. In: Alam, M. (eds) Evidence-Based Procedural Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-02023-1_56

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-02023-1_56

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-02022-4

  • Online ISBN: 978-3-030-02023-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation